Postoperative infections and long-term survival after LVAD implantation at a German tertiary care center: a retrospective cohort study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040827

Enrollment

216

Registered

2026-07-01

Start date

2026-07-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative infections after LVAD implantation

Interventions

Group 1: Retrospective analysis of patients who underwent first-time Heartmate 3 LVAD implantation at Klinikum Oldenburg between November 2015 and November 2025. Comparison of outcomes between patient

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 or older at the time of implantation. 2. First-time implantation of a Heartmate 3 LVAD. 3. Implantation period: November 2025 through November 2025.

Exclusion criteria

Exclusion criteria: 1. Secondary implantation of an HM3-type LVAD as part of a revision procedure involving device replacement from another model to an HM3. 2. Primary implantation of an HM3 as a permanent BiVAD or RVAD.

Design outcomes

Primary

Measure	Time frame
Overall five-year survival rate after first-time implantation of a Heartmate 3 LVAD.	—

Secondary

Measure	Time frame
1. Overall survival rate after initial Heartmate 3 LVAD implantation at 90 days, one year and two years. 2. Five-year survival rate free of late-onset MCS-specific infection more than 90 days after LVAD-implantation. 3. Incidence rate and cumulative incidence of MCS-specific and non-MCS-specific infections until postoperative day 90 after LVAD implantation. 4. Incidence rates and cumulative incidences of the non-infectious adverse events bleeding, neurologic dysfunction, device malfunction, hemolysis, right heart failure, renal dysfunction, cardiac arrhythmias, respiratory failure, venous thromboembolism, wound dehiscence and arterial non-CNS thromboembolism.	—

Measure

Time frame

1. Overall survival rate after initial Heartmate 3 LVAD implantation at 90 days, one year and two years. 2. Five-year survival rate free of late-onset MCS-specific infection more than 90 days after LVAD-implantation. 3. Incidence rate and cumulative incidence of MCS-specific and non-MCS-specific infections until postoperative day 90 after LVAD implantation. 4. Incidence rates and cumulative incidences of the non-infectious adverse events bleeding, neurologic dysfunction, device malfunction, hemolysis, right heart failure, renal dysfunction, cardiac arrhythmias, respiratory failure, venous thromboembolism, wound dehiscence and arterial non-CNS thromboembolism.

—

Countries

Germany

Contacts

Public ContactAxel Hamprecht

Universitätsinstitut für Medizinische Mikrobiologie und Virologie, Klinikum Oldenburg AöR

Hamprecht.Axel@klinikum-oldenburg.de+494414032160

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026